YMAB Investor Alert: Kaplan Fox Investigates Potential Securities Fraud at Y-mAbs Therapeutics, Inc.
11 nov. 2022 20h00 HE
|
Kaplan Fox & Kilsheimer LLP
NEW YORK, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors in Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the...
Y-mAbs Therapeutics, Inc. Shareholder Alert: Kaplan Fox Investigates Potential Securities Fraud
04 nov. 2022 09h00 HE
|
Kaplan Fox & Kilsheimer LLP
NEW YORK, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors in Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the...
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) Investor Alert: Kaplan Fox Investigates Potential Securities Fraud
31 oct. 2022 10h13 HE
|
Kaplan Fox & Kilsheimer LLP
NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors in Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the...
Breaking News for Y-mAbs Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm
27 oct. 2022 18h27 HE
|
Portnoy Law
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Oct. 27, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Y-mAbs Therapeutics, Inc....